Seres Therapeutics (NASDAQ:MCRB) Downgraded to Sell Rating by StockNews.com

StockNews.com downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

Other research analysts have also issued reports about the company. JPMorgan Chase & Co. lowered Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Stock Performance

MCRB stock opened at $0.98 on Wednesday. Seres Therapeutics has a 1 year low of $0.54 and a 1 year high of $2.05. The stock’s fifty day moving average is $0.80 and its two-hundred day moving average is $0.90. The stock has a market capitalization of $167.32 million, a price-to-earnings ratio of -4.26 and a beta of 2.06.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Seres Therapeutics by 12.1% in the first quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock valued at $5,213,000 after acquiring an additional 729,514 shares during the last quarter. Virtu Financial LLC acquired a new position in Seres Therapeutics during the 1st quarter valued at $73,000. Providence Wealth Advisors LLC boosted its holdings in Seres Therapeutics by 49.5% in the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 25,250 shares during the period. Point72 DIFC Ltd bought a new stake in Seres Therapeutics in the 2nd quarter valued at $64,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Seres Therapeutics in the 2nd quarter worth approximately $92,000. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.